Pier 88 Investment Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Pier 88 Investment Partners’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$257K	Sell	83,700 -13,440	-14%	-$51.9K	0.06%	101
2025 Q4	$397K	Sell	97,140 -21,420	-18%	-$106K	0.09%	99
2025 Q3	$579K	Buy	118,560 +44,050	+59%	+$231K	0.11%	86
2025 Q2	$377K	Sell	74,510 -20,280	-21%	-$99.6K	0.07%	94
2025 Q1	$501K	Sell	94,790 -66,940	-41%	-$488K	0.1%	86
2024 Q4	$1.09M	Buy	161,730 +27,820	+21%	+$187K	0.22%	50
2024 Q3	$882K	Buy	133,910 +109,210	+442%	+$783K	0.19%	61
2024 Q2	$185K	Buy	+24,700	New	+$215K	0.04%	92

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pier 88 Investment Partners's RXRX Position: Q1 2026 in Review

Pier 88 Investment Partners reduced its Recursion Pharmaceuticals (RXRX) stake by 14% in Q1 2026, selling an estimated $51.9K and leaving 83,700 shares worth $257K. The position accounts for 0.06% of the portfolio, ranked #101.

Pier 88 Investment Partners first reported a position in RXRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.09M in Q4 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Pier 88 Investment Partners held 83,700 shares of Recursion Pharmaceuticals worth $257K as of Q1 2026.
Pier 88 Investment Partners sold 13,440 Recursion Pharmaceuticals shares in Q1 2026, an estimated $51.9K.
Recursion Pharmaceuticals made up 0.06% of Pier 88 Investment Partners's portfolio in Q1 2026, its #101 holding.
Pier 88 Investment Partners first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Pier 88 Investment Partners's Recursion Pharmaceuticals position peaked at $1.09M in Q4 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Pier 88 Investment Partners's 13F filing for Q1 2026, filed 11 May 2026.